MDS Opens U.S. Central Lab

MDS Pharma Services has established its first central lab in the U.S., expanding its capabilities in late-stage pharmaceutical testing. The new 15,000-sq.-ft. facility, located in North Brunswick, NJ, is now fully operational and provides central lab support services for clinical trials.

In addition to standard safety testing, this facility provides esoteric testing including molecular biology, molecular genetics, flow cytometry, and immunoassays. These complex tests are used in drug development to evaluate targeted treatments for conditions such as cancer, autoimmune diseases, diabetes, and immune deficiencies.

“We established this lab to meet the growing demand from clients for a facility in the U.S. that offers both standard and complex testing to support the development of new treatments,” said MDS Pharma Services president, David Spaight. “This location is easily accessible to many pharmaceutical companies headquartered in the Northeastern U.S. It can accommodate clients who conduct clinical trials in and outside the country.”

The new lab has received accreditation from the College of American Pathologists (CAP) and also received a Level 1 certification from the National Glycohemoglobin Standardization Program for providing the highest levels of technical precision and accuracy in standard diabetic testing. This test is used to assess a diabetic’s overall wellbeing and to monitor the effectiveness of diabetic treatments.